Enfusion, Inc. EV/EBITDA LTM
| Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|
| EV/EBITDA LTM | 357.6x | (3.7x) | 86.9x | 74.9x |
Enfusion, Inc. (ENFN) EV/EBITDA LTM comparison analysis
General
LTM EV/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ENFN key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 59.0 0.0% | 79.6 34.8% | 111.7 40.4% | 150.3 34.6% | 174.5 16.1% | 201.6 15.5% |
| Cost of Goods Sold (COGS) | 17.0 | 21.4 | 31.8 | 47.1 | 57.6 | 64.9 |
% margin | 42.1 71.3% | 58.2 73.2% | 79.9 71.5% | 103.2 68.7% | 116.9 67.0% | 136.7 67.8% |
| Operating Expenses | 28.2 | 52.1 | 355.7 | 115.2 | 104.9 | 130.6 |
| Research & Development Expenses (R&D) | 4.1 | 6.3 | 153.4 | 17.2 | 19.9 | 26.7 |
| Selling, General & Administrative Expenses (SG&A) | 24.1 | 45.8 | 202.3 | 98.1 | 85.1 | 103.9 |
% margin | 13.9 23.5% | 6.1 7.6% | (275.9) (247.0%) | (12.0) (8.0%) | 11.9 6.8% | 6.2 3.1% |
| Interest Income | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 1.7 |
| Interest Expense | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 0.0 |
| Pre-tax Income | 13.1 | 4.5 | (281.7) | (12.2) | 11.5 | 7.4 |
% effective tax rate | 0.5 3.7% | 0.4 9.6% | 0.6 (0.2%) | 1.1 (8.8%) | 2.2 19.4% | 4.6 61.8% |
% margin | 12.7 21.4% | 4.1 5.1% | (282.2) (252.7%) | (13.3) (8.8%) | 6.0 3.5% | 2.8 1.4% |
| EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.10 | 0.02 |
| Diluted EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.07 | 0.01 |
% margin | 15.0 25.5% | 8.4 10.5% | (271.9) (243.4%) | (5.6) (3.7%) | 21.9 12.6% | 6.2 3.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enfusion, Inc.'s EV/EBITDA LTM?
As of today, Microsoft Corp's last 12-month EV/EBITDA LTM is 74.9x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual EV/EBITDA LTM for Enfusion, Inc. have been 50.6x over the past three years, and 37.9x over the past five years.
2) Is Enfusion, Inc.'s EV/EBITDA LTM Good?
As of today, Enfusion, Inc.'s EV/EBITDA LTM is 74.9x, which is higher than industry median of 3.6x. It indicates that Enfusion, Inc.'s EV/EBITDA LTM is Bad.